Excessive inflammation contributes to a variety of diseases, including cancer. The class of molecules known as resolvins appears to modify disease progression by decreasing inflammation, offering a potential therapeutic option, according to researchers at Roswell Park Cancer Institute.
Resolvins are produced when the body processes omega–3 fatty acids, which are found naturally in fish oil and vegetable oil.
The scientists examined a number of studies evaluating the role of these molecules in reducing acute and chronic inflammation, which has been associated with diseases including gastroenteritis, hepatitis, diabetes, neurological diseases and cancer.
Given their unique function with minimal side effects, resolvins could represent a new class of anti–inflammatory drugs.
Resolvins have been reported to improve the immune response, maintain lean body mass, improve quality of life and improve overall survival in patients with colorectal and pancreatic and esophageal cancer.
Resolvins in combination with evening primrose oil may be of importance in decreasing of inflammation, disease activity, and oxidative stress biomarkers, through increased activities of antioxidant enzymes in patients with Rheumatoid arthritis, in a similar fashion as widely prescribed ( potentially toxic and carcinogenic) anti-TNF drugs, like Enbrel, Remicade, Humira.